Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AlloNK1 in Advanced Nasopharyngeal Cancer
NCT07247201Phase 2Not yet recruiting
- Sponsor
- Singapore General Hospital
- Start
- Apr 2026
- Primary completion
- Apr 2026
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Lymphokine-Activated Killer Cells
- Countries
- 1
01
Overview
A Phase 2 trial of Natural killer cell infusion in nasopharyngeal carcinoma (NPC), sponsored by Singapore General Hospital. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
Natural killer cell infusion
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT07247201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07247201.